C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.

Bruce Spinowitz,Daniel W. Coyne,Charmaine E. Lok,Mario Fraticelli,Maher Azer,Sanjay Dalal,Giuseppe Villa,Steven J. Rosansky,Helena Adamis,Ulrich Beyer

C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.

2008

Bruce Spinowitz
Daniel W. Coyne
Charmaine E. Lok
Mario Fraticelli
Maher Azer
Sanjay Dalal
Giuseppe Villa
Steven J. Rosansky
Helena Adamis
Ulrich Beyer

Background/Aims: This Phase III study examined the efficacy and safety of C.E.R.A., a continuous erythropoietin receptor activator, given once every 2 weeks (Q2W) via subcutaneous o

Keywords:

Gastroenterology
Dialysis
Erythropoietin
Continuous erythropoietin receptor activator
Kidney disease
Hemoglobin
Every Two Weeks
Renal anemia
Endocrinology
Internal medicine
Diabetes mellitus
Surgery
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations